Ferda Kaygısız

  • Citations Per Year
Learn More
Methotrexate (MTX) is an anchor drug in the treatment of patients with rheumatoid arthritis (RA) and is the preferred first line agent for this condition. It has a well established efficacy and safety profile but gastrointestinal (GI) side effects of oral route may restrict its use in most of the patients [1, 2]. Subcutaneous MTX is reported to be well(More)
Serum adenosine deaminase (ADA) has been previously proposed to predict disease activity in patients with rheumatoid arthritis (RA). The aim of this study was to investigate the level of serum ADA, and the relationship between ADA and disease activity markers, in a group of patients with RA. A hundred and 10 patients with a diagnosis of RA were recruited(More)
  • 1